Payment overview · 2025
General Payments
$273.68
15 reported records · 11 companies
Healthcare provider profile · identity verified
Robert James Helm, MD
Allopathic & Osteopathic Physicians|Family Medicine · ELWOOD, IN · NPI 1104887066
Verified facts
What the public records show
CMS Open Payments records show Robert James Helm, MD received $273.68 in general payments during 2025 across 15 reported records.
Exact Sciences Corporation accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.18 | 16.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.81 | 15.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.27 | 10.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.41 | 9.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.30 | 9.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.34 | 8.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.22 | 7.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.35 | 6.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.47 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.45 | 5.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $13.88 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.68 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.41 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 112 |
| Losartan Potassium | Losartan Potassium | 334 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 75 |
| Lisinopril | Lisinopril | 228 | 60 |
| Metformin Hcl | Metformin Hcl | 219 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 52 |
| Jardiance | Empagliflozin | 165 | 27 |
| Sertraline Hcl | Sertraline Hcl | 148 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 36 |
| Eliquis | Apixaban | 137 | 30 |
| Valsartan | Valsartan | 137 | 38 |
| Gabapentin | Gabapentin | 127 | 41 |
| Alendronate Sodium | Alendronate Sodium | 124 | 40 |
| Omeprazole | Omeprazole | 124 | 36 |
| Simvastatin | Simvastatin | 121 | 33 |
| Famotidine | Famotidine | 116 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 29 |
| Montelukast Sodium | Montelukast Sodium | 96 | 24 |
| Glimepiride | Glimepiride | 93 | 23 |
| Meloxicam | Meloxicam | 92 | 32 |
| Furosemide | Furosemide | 88 | 23 |
| Trazodone Hcl | Trazodone Hcl | 85 | 21 |
| Glipizide | Glipizide | 84 | 22 |
| Prednisone | Prednisone | 79 | 54 |
| Donepezil Hcl | Donepezil Hcl | 78 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 22 |
| Ozempic | Semaglutide | 78 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 20 |
| Alprazolam | Alprazolam | 74 | 18 |
| Carvedilol | Carvedilol | 73 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 20 |
| Ezetimibe | Ezetimibe | 70 | 18 |
| Lorazepam | Lorazepam | 69 | 13 |
| Allopurinol | Allopurinol | 64 | 17 |
| Amoxicillin | Amoxicillin | 63 | 43 |
| Potassium Chloride | Potassium Chloride | 63 | 24 |
| Spironolactone | Spironolactone | 62 | 19 |
| Tramadol Hcl | Tramadol Hcl | 60 | 19 |
| Atenolol | Atenolol | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Torsemide | Torsemide | 48 | 17 |
| Celecoxib | Celecoxib | 47 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 11 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 11 |
| Cefdinir | Cefdinir | 36 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 19 |
| Estradiol | Estradiol | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 11 |
| Methylprednisolone | Methylprednisolone | 30 | 21 |
| Brilinta | Ticagrelor | 29 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 20 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 17 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Klor-Con M10 | Potassium Chloride | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 14 |
| Digoxin | Digoxin | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Metolazone | Metolazone | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.68 · 15 records | Exact Sciences Corporation | Cologuard Collection Kit, FANAPT, INSPIRE, Kerendia, Leqembi, MOUNJARO, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error